Skip to main content

Gastrointestinal (GI)

COVID-19 information

All gastrointestinal (GI) research is continuing as normal.

We are looking to deliver studies on how COVID-19 impacts inflammatory bowel disease (IBD) patients.

Inflammatory bowel disease (IBD) affects millions of people worldwide. Many IBD treatments are available but there is still no cure.

Gastrointestinal (GI) research focuses on IBD patients, in particular those who have Crohn’s disease or ulcerative colitis.

We have a range of studies focusing on new treatments and procedures that aim to improve the quality of life for patients living with IBD. Ultimately, we aim to cure these diseases.

We also look at conditions that occur as a result of IBD such as iron-deficiency anaemia and vitamin deficiencies.

Many patients consider research when other treatments have not worked or if it means avoiding surgery.

Common conditions and trial topics

The majority of our clinical trials focus on new targeted treatments that help treat Crohn’s disease and ulcerative colitis. These targeted treatments focus on specific cells in the gut and the reasons they cause inflammation.

We also have trials that look at and treat problems directly caused by IBD.

Some of our studies are observational. These studies do not involve a new drug but look at symptoms of IBD, the effects of these symptoms and the potential long term effects of the drugs being used.

We deliver endoscopy research that will help early detection and better diagnoses.

For the future we are looking at faecal matter transplantation (FMT) in the hope of curing these diseases.

Contact information

GI Research Nurses: Louise Bowlas and Lillie Bennett.

Last reviewed: 27 April 2021